Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

OPtimal Type 2 dIabetes Management Including Benchmarking and Standard Treatment in CEEMEA (OPTIMISE)

NCT01694758 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT01694758
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01694758 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
OPtimal Type 2 dIabetes Management Including Benchmarking and Standard Treatment in CEEMEA (OPTIMISE)
Lead sponsor
AstraZeneca
Phase
Observational
Overall status
Completed
Start date
November 30, 2012
Completion date
March 31, 2014
Enrollment
733 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

diabetes mellitus, non-insulin-dependent